The role of omalizumab in the treatment of severe allergic rhinitis based on clinical examples from real practice

Nasunova A.Yu., Nenasheva N.M.

Russian Medical Academy of Continuous Professional Education, Moscow, Russia

The prevalence of allergic rhinitis (AR) in Russia depends on the region, climate zone and occupies from 18 to 33.2% in the structure of respiratory allergic diseases. Against the background of an increase in the number of patients with respiratory allergies, a tendency towards aggravation of symptoms is noted. Thus, among patients with allergic rhinitis, 62.7% have moderate and severe forms. About 35-40% of patients, despite adequate treatment, according to the recommendations of medical specialists, do not achieve control over the symptoms of allergic rhinitis. Symptoms of allergic rhinitis, such as nasal congestion, nasal discharge, sneezing and itching, can significantly affect everyday life, quality of sleep and lead to psychological and social problems. The growing trend in the number of patients with uncontrolled symptoms of AR indicates the need to optimize approaches to therapy and implement the principles of personalized medicine in order to achieve a higher level of symptom control, increase patient compliance and satisfaction with treatment. One of the approaches that meets modern requirements for efficacy and safety in patients with uncontrolled severe symptoms of allergic rhinitis is the use of genetically engineered biological drugs. The efficacy and safety of biological drugs is confirmed by clinical examples from real practice. The article presents a series of clinical cases of severe uncontrolled symptoms of AR against the background of standard pharmacotherapy. The addition of biological drugs to standard pharmacotherapy, in particular omalizumab, allows for faster control of AR symptoms, increased treatment effectiveness and reduced need for symptomatic therapy. High efficacy and good tolerability and safety profile of omalizumab, as well as long-term experience of use in children and adults, make it an optimal choice for additional therapy of moderate-severe seasonal AR symptoms, allowing to maintain a good quality of life of patients during the palination season.

Keywords

About the Authors

Aysa Yu. Nasunova, Cand. Sci. (Med.), Teaching Assistant, Department of Allergology and Immunology, Russian Medical Academy of Continuous Professional Education, Moscow, Russia; aysanasunova@gmail.com, eLibrary SPIN: 9297-8223, ORCID: https://orcid.org/0009-0006-7116-9091 (corresponding author)
Natalia M. Nenasheva, Dr. Sci. (Med.), Professor, Head of the Department of Allergology and Immunology, Russian Medical Academy of Continuous Professional Education, Moscow, Russia; 1444031@gmail.com, eLibrary SPIN: 3363-6170, ORCID: https://orcid.org/0000-0002-3162-2510

Similar Articles